<DOC>
	<DOCNO>NCT01936961</DOCNO>
	<brief_summary>The purpose study use Immunochemotherapy +/- Hypofractionated Radiation complete response solid tumor</brief_summary>
	<brief_title>Study Immunochemotherapy +/- Hypofractionated Radiation Complete Response Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>1 . Patient definitive histologically cytologically confirm metastatic NSCLC , colon , TNB cancer . 2 . Patient one metastatic tumor measurable CT scan ( PET/CT , patient allergic CT contrast medium ) . 3 . For NSCLC patient without EGFR ALK abnormalities amenable EGFR ALK target therapy : patient must receive least 2 3 cycle either first secondline systemic therapy treatment metastatic disease . For NSCLC patient EGFR ALK abnormalities amenable receive EGFR ALK target therapy : patient must progress firstline EGFR ALK target therapy receive least 2 3 cycle either second thirdline systemic therapy treatment metastatic disease . 4 . For colon cancer patient : patient must patient must receive least 2 3 cycle either first secondline systemic therapy treatment metastatic disease . 5 . For TNB cancer patient , patient must patient must receive least 2 3 cycle either first secondline systemic therapy treatment metastatic disease . 6 . At time screening , patient must scan ( within 28 day ) show stable disease RECIST 1.1 . Where applicable , measurable tumor marker ( e.g . CA199 , CEA , CA125 ) collect within 14 day must least 10 % less baseline value recent systemic therapy ( baseline value abnormal elevate ) . 7 . Patient adequate biological parameter demonstrate follow blood count time screening : 8 . Absolute neutrophil count ( ANC ) &gt; 1500 mm3 , platelet count ≥ 100×109 L , hemoglobin ≥ 9 g/dL . 9 . Serum creatinine ≤2.0 , total bilirubin ≤ 2 mg/dL , AST/ALT ≤ 5 time upper limit normal range 10 . Thyroid stimulate hormone ( TSH ) within institutional normal limit . If TSH upper limit normal range , free T4 within institutional normal limit acceptable . 11 . Persistent prior systemic therapy nonhematologic AE grade ≥2 ( except alopecia correctable electrolyte abnormality supplementation ) 12 . Patient Karnofsky performance status ( KPS ) ≥ 70 . 13 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must willing use acceptable contraceptive method ( abstinence , oral contraceptive double barrier method ) duration study 30 day follow last dose study drug , must negative urine serum pregnancy test within 2 week prior begin treatment trial . 1 . Active clinically serious infection &gt; CTCAE ( version 4.03 ) Grade 2 . 2 . Serious nonhealing wound , ulcer , bone fracture . 3 . Patient known brain metastasis , unless previously treat wellcontrolled least 1 month ( define clinically stable , edema , steroid stable 2 scan least 4 week apart ) . 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 5 . Patient know active infection HIV , hepatitis B , hepatitis C ( patient NOT require test presence virus prior therapy protocol ) . 6 . Requiring daily corticosteroid dose ≥ 7.5 mg prednisone equivalent per day . 7 . Patient undergone major surgery , diagnostic surgery ( e.g. , surgery do obtain biopsy diagnosis without removal organ ) , within 4 week prior Day 1 treatment study . 8 . Patient history allergy hypersensitivity study drug excipients , patient exhibit event outline Contraindication Special Warnings Precautions section product comparator SmPC Prescribing Information . 9 . Patient serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise patient 's safety study data integrity . 10 . Patient receive anticancer therapy participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Cancer</keyword>
</DOC>